Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 3, 2022- Interim results reported in October 2021 from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80 mg/kg multi-dose administered intravenously, or IV.
-
Feb 22, 2022
-
Jan 4, 2022- Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinoma and uveal melanoma patients in dose escalation of INBRX-106 in combination with Keytruda®
-
Dec 1, 2021- Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma
-
Nov 3, 2021
-
Oct 12, 2021-- Interim results from the Phase 1 study show a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose administered intravenously, or IV.
-
Oct 11, 2021- Event to be webcast live on Tuesday, October 12, 2021, at 5:30 a.m. PT -
-
Jun 21, 2021- Median progression-free survival (PFS) of 7.6 months and disease control rate of 87.5% observed in conventional chondrosarcoma patients in Phase 1
-
May 13, 2021
-
Jan 13, 2021Registration-enabling study expected to begin dosing in the second or third quarter of this year
-
Nov 13, 2020- Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th
-
Nov 11, 2020- Disease control observed in 92% of patients
-
Sep 3, 2019-INBRX-109 was well-tolerated; a maximum tolerated dose was not reached-
-
May 30, 2019Up to $162.5M in upfront, cost sharing and milestone payments, and escalating royalties into the high teens assuming exercise of the option
-
Sep 15, 2015Inhibrx’s AAT-Fc therapeutic should benefit patients with enhanced efficacy and less frequent dosing